Please enable Javascript
Cailin Conner
Articles by Cailin Conner
Venetoclax Plus Lenalidomide, Rituximab ‘Safe’ in Frontline MCL Treatment
Cailin Conner
Mantle Cell Lymphoma
|
October 6, 2023
The investigators conceded the longer follow-up is needed but the results are promising.
Read More
Acalabrutinib Exhibits Better Benefit-Risk Profile, Lower Cardiovascular Toxicity Versus Ibrutinib in CLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 25, 2023
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Read More
Highly Complex Karyotypes, Translocations Are Adverse Prognostic Factors in Venetoclax-Based Combinations for CLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 22, 2023
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Read More
Favorable Long-term PFS in Patients with CLL, Mutated IGHV Following FCR Treatment
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 25, 2023
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Read More
Tagraxofusp Granted Orphan Drug Designation to Treat BPDCN
Cailin Conner
Print
|
October 11, 2023
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
Read More
Study Evaluates CLL Treatment Approaches in Turkey
Cailin Conner
Meeting News
|
September 10, 2023
Noteworthy regional disparities were noticed in treatment strategies.
Read More
Study Finds Comparable Outcomes of Multihit Versus Single-Hit TP53 Alterations in CLL
Cailin Conner
Chronic Lymphocytic Leukemia
|
September 10, 2023
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Read More
Improved Outcomes in Patients Treated with Ruxolitinib After Hydroxyurea
Cailin Conner
Meeting News
|
September 10, 2023
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
Read More
Thromboembolic Events Among Patients with Polycythemia Vera Linked to Significant Costs, All-Cause Mortality
Cailin Conner
Meeting News
|
September 10, 2023
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Read More
Financial, Diagnostic Restraints Pose Challenge to Patients with Polycythemia Vera in Low-Income Countries
Cailin Conner
Polycythemia Vera
|
September 9, 2023
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Read More
CAR-HEMATOTOX Score Identifies Patients with MCL at Risk of Poor Outcomes After Brexu-Cel
Cailin Conner
Mantle Cell Lymphoma
|
February 8, 2024
Researchers developed the score because no early risk-stratification system has been validated in this setting.
Read More
Combination Therapy Has Potential in HIV-Related Classical Hodgkin Lymphoma
Cailin Conner
Hodgkin Lymphoma
|
August 10, 2023
The primary objective of the phase II portion was to evaluate the two-year PFS rate with the treatment.
Read More